Treatment time cut for microwave prostate therapy:
This article was originally published in Clinica
Executive Summary
Urologix has begun a US clinical trial to assess the effect of reducing the treatment time of its non-surgical microwave heat ablation therapy for benign prostatic disease. Four patients have already been treated successfully with the Targis system after researchers more than halved the standard one-hour therapy, said the Minneapolis, Minnesota-based company. Positive results from the trial, which is being carried out under a supplemental investigational device exemption from the FDA, could lead to shorter treatment time without compromising patient comfort, complications or long-term clinical outcomes, according to Urologix.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.